SCHEMBL496548

SCHEMBL496548

O=C(O)c1ccc(F)nc1NC1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 2/20 0.43
HCAR3 P49019 2/20 0.42
KMT2A Q03164 1/20 0.41
SYK P43405 1/20 0.41
TLR7 Q9NYK1 2/20 0.40
MERTK Q12866 1/20 0.40
CTSL P07711 1/20 0.39
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
CSNK2A2 P19784 1/20 0.39
CSNK2B P67870 1/20 0.39
CSNK2A1 P68400 1/20 0.39
GBA1 P04062 1/20 0.39
MAPT P10636 1/20 0.39
PDE5A O76074 1/20 0.39
ACP1 P24666 1/20 0.39
OGG1 O15527 1/20 0.39
STAT6 P42226 1/20 0.38
ATM Q13315 1/20 0.38
KDM4E B2RXH2 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL495797 0.82 KMT2A (0.43) MAPK8HCAR3KMT2ASYKMERTK
SCHEMBL6644500 0.82 CHRM3 (0.44) MAPK8HCAR3KMT2ASYKMERTK
SCHEMBL495713 0.80 NR2F2 (0.53) KMT2AMAPTKDM4EALDH1A1
SCHEMBL496141 0.79 POLB (0.54) MAPK8HCAR3SYKMERTKCTSL
SCHEMBL2344874 0.79 MAPK8 (0.40) MAPK8HCAR3KMT2ASYKMERTK
SCHEMBL4402475 0.78 SYK (0.45) MAPK8HCAR3KMT2ASYKMERTK
SCHEMBL16878622 0.74 HCAR3 (0.41) HCAR3SYKCSNK2A2CSNK2BCSNK2A1
SCHEMBL10468298 0.73 ROCK2 (0.43) MAPK8HCAR3KMT2ASYKMERTK
SCHEMBL17363112 0.73 TLR7 (0.43) HCAR3KMT2ASYKTLR7MERTK
SCHEMBL15689013 0.73 ALDH1A1 (0.56) MAPK8HCAR3KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1955697-B1 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER ASTELLAS PHARMA INC (JP) 2012-05-02 EP disclosed
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 US disclosed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 US disclosed
EP-1955697-A1 2-AMINOBENZAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE TRPV1, TRPV2, TRPV5 MAPK8 3178/4885HCAR3 98/4885KMT2A 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.